$20.50+0.31 (+1.54%)
Evommune, Inc.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneou...
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Evommune's (EVMN) experimental drug for chronic hives may have broader uses if upcoming trial result
Biotech IPOs gain long-lost momentum, and pharma companies find a way around the White House’s harsh tariffs.